Could a malaria drug boost leukemia treatment?

NCT ID NCT07022743

Ongoing Disease control Sponsor: Obafemi Awolowo University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial in Nigeria tests whether adding artesunate, a malaria drug, to the standard CML medication imatinib can improve treatment outcomes. 75 adults with chronic myeloid leukemia will receive either imatinib alone or imatinib plus artesunate. The goal is to see if the combination leads to better molecular remission and is safe for long-term use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: imatinib and artesunate combination
What this could lead to: If it works, this could offer a more affordable and effective treatment option for CML patients, especially in low-income countries where second-line drugs are unavailable.
What could go wrong: This is a small Phase 2 trial with only 75 participants, so results may not apply to everyone. Artesunate's long-term safety for CML is not yet proven, and the combination may not work better than imatinib alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA (CML)

Contacts and locations

Locations

Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife

Ile-Ife, Osun State, 3408, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.